Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Gastroenterology | Family Medicine
Clinical Trials: Colorectal Cancer
A listing of clinical trials currently looking for volunteers to enroll in Colorectal Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Birmingham Hematology and Oncology
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Birmingham : University of Alabama Birmingham Comprehensive Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Birmingham : Birmingham Hematology and Oncology Associates, LLC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Birmingham : Achieve Clinical Research LLC
Head to Head Study Epi proColon and FIT
Birmingham :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Arizona
Gilbert : Banner MD Anderson Cancer Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Glendale : Arizona Center for Cancer Care
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Glendale : Arizona Center for Cancer Care
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Glendale : Arizona Center for Cancer Care
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Hot Springs : Genesis Cancer Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
View More »
Scottsdale : Pinnacle Oncology Hematology
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Sedona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tucson : Arizona Clinical Research Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tucson : Visions Clinical Research
Head to Head Study Epi proColon and FIT
Arkansas
California
Escondido : Southwest Cancer Care
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Monterey : Monterey Bay Oncology
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Oxnard : Ventura County Hematology Oncology Specialists
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Alhambra : Central Hematology Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Anaheim : Pacific Cancer Medical Center, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Anaheim : Pacific Medical Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Bakersfield : Comprehensive Blood and Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Bakersfield : Comprehensive Blood and Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Bellflower :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Burbank : Providence St. Joseph Medical Center-Disney Family Cancer Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Burbank : East Valley Hematology and Oncology Medical Center
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Burbank : Providence St. Joseph Medical Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Corona : Wilshire Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Duarte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Duarte : City of Hope Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Fountain Valley : Compassionate Cancer Care Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Fountain Valley :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Fresno :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Fresno : California Cancer Associates for Research and Excellence
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Fullerton : Saint Jude Heritage Healthcare
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Fullerton : St. Jude Heritage Healthcare
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Gilroy : Ronald H. Yanagihara, MD
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Glendale : White Memorial Medical Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Greenbrae : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Hayward :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
La Jolla : UCSD Moores Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
La Jolla, : University of California San Diego
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Laguna Hills : South Orange County Surgical Medical Group
Head to Head Study Epi proColon and FIT
Long Beach : Pacific Shores Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Los Angeles : Comprehensive Hematology Oncology Centers, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Los Angeles : UCLA Community Oncology Practice
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Los Angeles : Healthcare Partners Medical Group
Head to Head Study Epi proColon and FIT
Los Angeles : USC Norris Comprehensive Cancer Center
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Los Angeles :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Northridge : The Thomas and Dorothy Leavey Cancer Center Northridge Hospital Medical Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Oakland : Hematology Oncology Associates
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Oakland :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Oceanside : North County Oncology Medical Clinical Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Orange : UC Irvine Medical Center, Division of Hematology/Oncology
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Orange : Hematology Oncology Medical Group of Orange County
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Palo Alto : Stanford University Medical Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Pomona : Wilshire Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Rancho Cucamonga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Redondo Beach : Cancer Care Associates Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Redondo Beach : Pacific Shores Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Roseville :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Sacramento :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
San Diego : Sharp Health Care
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
San Diego : Sharp Memorial Hospital
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
San Francisco :
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
San Francisco : CPMCRI / Pacific Hematology Oncology Associates
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
San Francisco :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
San Francisco : Pacific Hematology Oncology Associates
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
San Jose : San Jose Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
San Jose :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
San Jose : San Jose Medical Group
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
San Luis Obispo : Coastal Integrative Cancer Care
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Santa Clara :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Santa Maria : Central Coast Medical Oncology Corp
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
South San Francisco :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Vallejo : Kaiser Permanente Oncology Clinical Trials
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Vallejo :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Walnut Creek :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Colorado
Aurora : University of Colorado Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Denver : Eastern Colorado Health Care System - Denver VA
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Denver : Rocky Mountain Cancer Centers
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Denver :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Denver :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Grand Junction : Saint Mary's Regional Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Grand Junction : St. Mary's Hospital Regional Cancer Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Wheat Ridge : Mountain Blue Cancer Care Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Connecticut
Bridgeport : Gastroenterology Associates of Fairfield County
Head to Head Study Epi proColon and FIT
Middletown : Middlesex Hospital Cancer Center
Head to Head Study Epi proColon and FIT
New Haven :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
New Haven : Yale Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Stamford : Stamford Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
View More »
Stamford : Hematology Oncology Associates, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Stamford : The Stamford Hospital
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Trumbull :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Delaware
Newark : Christiana Care Health Services
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
District of Columbia
Washington : George Washington University - Medical Faculty Associates
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Washington : Georgetown University
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Washington : Georgetown University Medical Center
Lapatinib and Cetuximab in Patients With Solid Tumors
Washington : Georgetown University
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Washington : Georgetown Lombardi Comprehensive Cancer Center
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Washington : Georgetown Lombardi Comprehensive Cancer Center
PD-0332991, 5-FU, and Oxaliplatin for Advanced Colorectal Cancer
Florida
Jacksonville : Integrated Community Oncology Network
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Miami : Advanced Medical Specialties
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
New Port Richey : Pasco Pinellas Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Boynton Beach : University Cancer Institute
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Boyton Beach : Zasa Clinical Research
Head to Head Study Epi proColon and FIT
Fort Lauderdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Fort Myers :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Ft. Myers : Florida Cancer Specialists
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Gainesville : University of Florida, Davis Cancer Center (VA)
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Gainesville : Florida Cancer Specialists
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Hollywood : Center for Gastrointestinal Disorders
Head to Head Study Epi proColon and FIT
Hollywood :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Jacksonville : Mayo Clinic Florida Hematology/Oncology
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Jacksonville :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Miami : Advance Medical Research Service Corp.
Head to Head Study Epi proColon and FIT
Miami :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Miami Beach : Research Site
A Phase 1 Study to Evaluate MEDI4736
Ocala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Orange City : Compass Research, LLC
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Orlando : Florida Hospital Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Orlando :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Orlando : MD Anderson Cancer Center Orlando
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Port Orange : Accord Clinical Research, LLC
Head to Head Study Epi proColon and FIT
Port St Lucie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Port St. Lucie : Hematology Oncology Associates of the Treasure Coast
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Rockledge : Cancer Care Centers of Brevard
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
St. Petersburg : Florida Cancer Specialists
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Tampa : Research Site
A Phase 1 Study to Evaluate MEDI4736
Tampa : Stedman Clinical Trials, LLC
Head to Head Study Epi proColon and FIT
Tampa : H. Lee Moffitt Cancer Center (Moffitt Cancer Center)
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Titusville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Weston : Cleveland Clinic Florida
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Georgia
Atlanta : Peachtree Hematology and Oncology Consultants, PC
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Atlanta : Peachtree Hematology Oncology Consultants, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Atlanta :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Augusta : Research Site
A Phase 1 Study to Evaluate MEDI4736
Augusta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Gainesville : Northeast Georgia Medical Center
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Lawrenceville : Suburban Hematology Oncology Associates, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Lawrenceville : Suburban Hematology-Oncology Assoc., PC
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Macon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Hawaii
Honolulu : Queen's Medical Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Honolulu : University of Hawaii
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Honolulu : Kaiser Foundation Hospitals
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Honolulu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Illinois
Arlington Heights : Cancer Care & Hematology Specialists of Chicagoland
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Berwyn : Vanguard Health
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Centralia : University Hematology Oncology, Inc
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Chicago : Northwestern University
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Chicago : Hematology/Oncology Associates
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
View More »
Chicago : Northwestern University, Northwestern Medical Faculty Foundation
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Chicago : Northwestern University
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Chicago : The University of Chicago Medical Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Chicago : University of Illinois at Chicago
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Chicago : Weiss Memorial Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Chicago :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Chicago : Jesse Brown VA
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Chicago : Rush University Gastroenterologists
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Chicago : Stroger Cook County
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Chicago : University of Illinois at Chicago
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Galesburg : Medical and Surgical Specialists
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Galesburg : Medical and Surgical Specialists
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Harvey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Harvey : Ingalls Memorial Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Harvey :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Harvey : Ingalls Cancer Research Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Joliet : Joliet Oncology-Hematology Associates, Ltd.
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Joliet :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Maywood :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Park Ridge : Oncology Specialists,S.C. Center for Advanced Care
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Peoria : Illinios Cancer Care
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Peoria : Illinois CancerCare, P.C.
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Peoria :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Peoria : Illinois Cancer Care, P.C.
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Skokie : Edward Kaplan and Associates
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Springfield : Springfield Clinic
Head to Head Study Epi proColon and FIT
Urbana : Carle Cancer Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Warrenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Zion : Midwestern Regional Medical Center
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Indiana
Goshen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Goshen :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Indianapolis : Investigative Clinical Research of Indiana, LLC
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Indianapolis : Indiana University Simon Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
View More »
Indianapolis : Indiana University Simon Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Lafayette : Horizon Oncology Research, Inc.
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Muncie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Terre Haute : Providence Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Terre Haute : Providence Medical Group
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Terre Haute :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Iowa
Clive : Medical Oncology & Hematology Associates (Clinic #3)
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Des Moines : Iowa Oncology Research Association
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Des Moines : Medical Oncology & Hematology Associates (Clinic #2)
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Des Moines : Medical Oncology & Hematology Associates (Clinic #1)
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Sioux City : Siouxland Hematology-Oncology Associates, LLP
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Kansas
Wichita : Cancer Center of Kansas
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Kentucky
Lexington : Central Baptist Hospital
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Louisville : Owsley Brown Frazier Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Louisville : University of Louisville
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Louisville :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Louisville : Louisville Oncology
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
View More »
Louisville :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Louisville : University of Louisville/James Brown Cancer Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Paducah :
A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Louisiana
Baton Rouge : Gastroenterology Associates
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Baton Rouge : Mary Bird Perkins Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Metairie : New Orleans Research Institute
Head to Head Study Epi proColon and FIT
Shreveport : Louisiana Research Center
Head to Head Study Epi proColon and FIT
Maine
Maryland
Bethesda : Center for Cancer and Blood Disorders
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Annapolis : Anne Arundel Medical Center, Annapolis Oncology Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Baltimore : University of Maryland Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Baltimore : John Hopkins University
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Baltimore : Weinberg Cancer Institute at Franklin Square
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Bethesda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Bethesda :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Bethesda : National Capital Clinical Research Consortium
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Bethesda : Center for Cancer and Blood Disorders
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Chevy Chase : Metropolitan Gastroenterology Group
Head to Head Study Epi proColon and FIT
Chevy Chase : Chevy Chase Clinical Research
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Glen Burnie : Greenbaum Cancer Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Rockville : Associates of Oncology Hematology, P.C.
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Rockville :
A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Massachusetts
Boston : Tufts Medical Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Boston :
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Boston : Dana Farber Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
Boston : Dana-Farber Cancer Institute
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Boston : Massachusetts General Hospital
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Brockton : Commonwealth Clinical Trials
Head to Head Study Epi proColon and FIT
Brockton : Commonwealth Clinical Studies
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Burlington : Lahey Clinic
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Michigan
Detroit : Karmanos Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Ann Arbor : University of Michigan Hospital and Health Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Ann Arbor : University of Michigan Comprehensive Cancer Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Ann Arbor : St. Joseph Mercy Hospital
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Ann Arbor : St. Joseph Mercy Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Detroit : Henry Ford Hospital
Association Between Hepatitis C Infection and Renal Cell Carcinoma
Detroit : Henry Ford Health System
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Detroit : Barbara Ann Karmanos Cancer Institute
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Detroit :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Detroit : Henry Ford Health System
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Grand Rapids : Grand Rapids Clinical Oncology Program
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Kalamazoo : West Michigan Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Royal Oak : William Beaumont Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Royal Oak : Beaumont Hospital
Head to Head Study Epi proColon and FIT
Troy : Troy Gastroenterology PC Center for Digestive Health
Head to Head Study Epi proColon and FIT
Minnesota
Duluth : Essentia Health Duluth CCOP
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Minneapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Minneapolis : Virginia Piper Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Minneapolis : Virginia Piper Cancer Institute
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Minneapolis : University of Minnesota
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
View More »
Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Rochester : Mayo Clinic
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Saint Louis Park : Regions Hospital
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Saint Louis Park : St. John's Hospital
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Saint Louis Park : Metro Minnesota CCOP
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
St Louis Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
St. Cloud : Coborn Cancer Center/ CentraCare Health Plaza
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Mississippi
Tupelo : Hematology and Oncology Associates at BridgePoint
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Missouri
Bridgeton : Saint Louis Cancer Care LLP
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Bridgeton :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Columbia : Ellis Fischel Cancer Center at University of Missouri- Columbia
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Jefferson City : Jefferson City Medical Group
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Kansas City :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Kansas City : Research Medical Center
Head to Head Study Epi proColon and FIT
Kansas City : Saint Luke's Cancer Institute
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Saint Joseph : Saint Joseph Oncology, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Montana
Nebraska
Lincoln : Southeast Nebraska Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Lincoln :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Nevada
Las Vegas : Comprehensive Cancer Centers of Nevada
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Henderson : Comprehensive Cancer Centers of Nevada
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Las Vegas : Comprehensive Cancer Centers of Nevada
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Las Vegas : CCCN
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
New Hampshire
Lebanon : Dartmouth-Hitchcock Medical Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Portsmouth : Portsmouth Regional Hospital
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
New Jersey
Cherry Hill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Cherry Hill :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Elizabeth : Trinitas Comprehensive Cancer Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Hackensack : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Morristown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Morristown :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Morristown : Hematology-Oncology Associates of Northern NJ
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Teaneck : Holy Name Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
New Mexico
Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Albuquerque :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Farmington :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Las Cruces :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Santa Fe :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
New York
Bronx : Biomedical Research Alliance of New York
Metastatic Colorectal Carcinoma
View More »
Binghampton : Binghampton Gastroenterology Associates
Head to Head Study Epi proColon and FIT
Bronx : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Bronx : Montefiore Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Cooperstown : Bassett Healthcare Center
Head to Head Study Epi proColon and FIT
Great Neck : Long Island Gastrointestinal Group
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Hudson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Jamaica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Lake Success :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
New Windsor : Mid Hudson Medical Research, PLLC
Head to Head Study Epi proColon and FIT
New York : Memorial Sloan Kettering Cancer Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
New York : NYU Cancer Institute
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
New York : Beth Israel Comprehensive Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
New York : New York Gastroenterology Associates, LLP
Head to Head Study Epi proColon and FIT
New York : Montefiore - Einstein Cancer Care Center
Head to Head Study Epi proColon and FIT
New York : Mount Sinai Medical Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
New York : Mount Sinai School of Medicine
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
New York :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Syracuse : Research Foundation of State University of New York
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
North Carolina
Asheville : Asheville Gastroenterology Associates
Head to Head Study Epi proColon and FIT
Asheville : Asheville Gastroenterology
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Burlington : Alamance Regional Medical Center Cancer Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Chapel Hill :
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Chapel Hill : University of North Carolina at Chapel Hill
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
View More »
Charlotte : Carolinas Hematology-Oncology Associates
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Carolinas Hematology-Oncology Associates - Ballantyne
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Carolinas Hematology-Oncology Associates - University
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Levine Cancer Institute
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Mecklenburg Medical Group - Morehead
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Mecklenburg Medical Group - South Park
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Carolinas Hematology-Oncology - Ballantyne
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Carolinas Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Levine Cancer Institute - Blumenthal Cancer Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Mecklenburg Medical Group
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Mecklenburg Medical Group - Pineville
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Charlotte : Presbyterian Hospital Cancer Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Concord : Northeast Oncology Associates
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Durham : Duke University Medical Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Durham :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Greensboro :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
High Point : Emerywood Hematology and Oncology
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
High Point :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Monroe : Mecklenburg Medical Group - Carolinas Cancer Associates
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Raleigh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Winston Salem : Piedmont Hematology Oncology Associates PA
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Winston-Salem : Digestive Health Specialists, PA
Head to Head Study Epi proColon and FIT
Winston-Salem : Piedmont Medical Research Associates, LLC
Head to Head Study Epi proColon and FIT
Winston-salem :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
North Dakota
Bismarck : Legacy Pharma Research
Metastatic Colorectal Cancer with wild-type KRAS tumors.
View More »
Bismarck : Medcenter One
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Fargo : Lillestol Research, LLC
Head to Head Study Epi proColon and FIT
Grand Forks : Altru Health Systems
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Ohio
Canton : Tri Country Hematology / Oncology
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Canton : Gabrail Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Cincinatti : Oncology Hematology Care, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Cincinnati :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
View More »
Cincinnati : Oncology Hematology Care, Inc
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Cincinnati : Gastroenterology Research Consultants of Greater Cincinnati
Head to Head Study Epi proColon and FIT
Cincinnati : TriHealth Oncology Institute/Oncology Partners Network
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Columbus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Columbus :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Middletown : Signal Point Clinical Research Center, LLC
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Middletown : Signal Point Clinical Research Center, LLC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Sylvania : Hickman Cancer Center at Flower Hospital
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Toledo :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Toledo : Mercy Cancer Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Toledo :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Toledo : Toledo Community Oncology Program- Toledo Community Hospital
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Wilmington : Oncology Hematology Care, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Oklahoma
Oklahoma City :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Oklahoma City :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Tulsa : Cancer Care Associates
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Oregon
Pennsylvania
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Philadelphia : University of Pennsylvania
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Abington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Beaver : UPMC Cancer Center Beaver
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bethlehem : St. Luke's Hospital and Health Network
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Camp Hill : PinnacleHealth
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Dunmore :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Greensburg : UPMC Cancer Center Arnold Palmer at Mountain View
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Harrisburg : Pinnacle Health
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Kingston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Media :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Philadelphia : Fox Chase Cancer Center
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Philadelphia :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Pittsburgh : UPMC Hillman Cancer Center
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Pittsburgh : UPMC Hillman Cancer Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Pittsburgh : University of Pittsburgh Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Pittsburgh : UPMC Cancer Center Passavant
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Uniontown : UPMC Cancer Center Uniontown
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Willow Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Rhode Island
East Providence : Pharma Resource
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Providence : The Miriam Hospital
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Providence : Rhode Island Hospital
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
South Carolina
Charleston : Medical University of South Carolina
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Charleston : Charleston Hematology Oncology Associates
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Columbia : South Carolina Oncology Associates
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Columbia :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Mt. Pleasant : Coastal Carolina Research Center
Head to Head Study Epi proColon and FIT
Tennessee
Chattanooga :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Chattanooga : Chattanooga Oncology Hematology Associates
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Collierville : Family Cancer Center
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Germantown : Gastro One
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Germantown : The Jones Clinic
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
View More »
Kingsport : Gastroenterology Associates
Head to Head Study Epi proColon and FIT
Knoxville : Center for Biomedical Research
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Knoxville : Center for Biomedical Research - Oncology
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Knoxville : Tennessee Cancer Specialists
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Nashville : Tennessee Oncology
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
Nashville : Tennessee Oncology, PLLC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Nashville :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Nashville : Tennessee Oncology, PLLC
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Nashville :
Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Nashville : Sarah Cannon Research Institute
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Texas
Dallas : Mary Crowley Cancer Research Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Dallas : Texas Oncology - Baylor - Charles A. Sammons Cancer Center
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Fort Worth : Texas Oncology - Fort Worth
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Round Rock : Texas Oncology - Seton Williamson
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Abilene : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Arlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Beaumont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Bedford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Carrolton : Independent Clinical Research, LLC
Head to Head Study Epi proColon and FIT
Corpus Christi :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Dallas : University of Texas Southwestern Medical Center at Dallas
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Dallas : Mary Crowley Cancer Research Center
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Denton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Flower Mound : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Fort Worth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Fort Worth : Center for Cancer and Blood Disorders, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Fort Worth :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Fort Worth : The Center for Cancer and Blood Disorders
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
Ft. Worth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Garland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Houston : UT MD Anderson Cancer Center
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Houston : UT MD Anderson Cancer Center
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Houston : UT MD Anderson Cancer Center
Azacitidine and CAPOX in Metastatic Colorectal Cancer
Houston : UT MD Anderson Cancer Center
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
Houston :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Lubbock : Joe Arrington Cancer Research and Treatment Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Mcallen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Odessa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Round Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
San Antonio : South Texas Oncology and Hematology, PA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
San Antonio :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Sherman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Sugar Land : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Temple : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tyler : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tyler : Digestive Health Specialists
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Waco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Weatherford : The Center for Cancer and Blood Disorders
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Webster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Wichita Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Utah
Bountiful : Utah Cancer Specialists - Bountiful/Lakeview Office
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Layton : Utah Cancer Specialists - Layton/Davis Office
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Murray : Utah Cancer Specialists - Cottonwood Office
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Ogden : Northern Utah Associates
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Ogden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Provo : Utah Cancer Specialists - Provo Office
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Salt Lake City :
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Salt Lake City : Utah Cancer Specialists
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Salt Lake City : Utah Cancer Specialists
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Salt Lake City : Utah Cancer Specialists - Salt Lake Clinic
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Salt Lake City : Utah Cancer Specialists - Salt Lake Regional
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Salt Lake City : St. Mark's Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Salt Lake City : Salt Lake Research
Head to Head Study Epi proColon and FIT
Salt Lake City : Huntsman Cancer Institute
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Salt Lake City : Utah Cancer Specialists
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
West Jordan : Utah Cancer Specialists - Jordan Valley
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Virginia
Fairfax : Virginia Cancer Specialists
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Newport News : Peninsula Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Newport News : Virginia Oncology Associates
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Roanoke : Oncology and Hematology Associates of SW Virginia, Inc, DBA Blue Ridge Cancer Care
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Chesapeake : Gastroenterology Associates of Tidewater
Head to Head Study Epi proColon and FIT
Fairfax : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Fredericksburg : Hematology/Oncology Associates of Fredericksburg
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Midlothian : Virginia Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Newport News : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Norfolk : Clinical Research Associates of Tidewater
Head to Head Study Epi proColon and FIT
Norfolk : Digestive and Liver Disease Specialists
Head to Head Study Epi proColon and FIT
Norfolk : Digestive and Liver Disease Specialists
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Richmond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Richmond : Virginia Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Richmond : Virginia Piper Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Richmond :
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Winchester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Washington
Kennewick : Columbia Basin Hematology and Oncology
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Spokane : Medical Oncology Associates
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Tacoma : MultiCare Health System
Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer
View More »
Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Seattle : University of Washington
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Spokane : Evergreen Hematology and Oncology
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Wisconsin
Green Bay : St. Mary's Hospital / Green Bay Oncology
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Green Bay : St. Vincent Hospital / Green Bay Oncology
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Madison : Dean Foundation Medical Research
Head to Head Study Epi proColon and FIT
Madison : University of Wisconsin
Head to Head Study Epi proColon and FIT
Madison :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
View More »
Milwaukee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Milwaukee : Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Milwaukee : Aurora St. Luke's Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Wauwatosa :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Argentina
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Caba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Santa Fe : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tucumain : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Viedma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Australia
Adelaide : Royal Adelaide Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Adelaide : The Queen Elizabeth Hospital
Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
Ballarat : Ballarat Health Services
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Bedford Park : Flinders Medical Centre
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Bedford Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Bedford Park : Flinders Medical Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Brisbane :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Camperdown :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Concord : Concord Repatriation General Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Darlinghurst :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Darlinghurst : St. Vincent's Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
East Bentleigh : Monash Medical Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Elizabeth Vale : Lyell McEwin Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Footscray : Western Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Frankston : Peninsula Oncology Centre
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Frankston : Peninsula Oncology Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Heidelberg :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Heidelberg : Austin Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Herston : Royal Brisbane and Women's Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Hobart : Royal Hobart Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Hobart : Royal Hobart Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Kogarah : St George Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Launceston :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Liverpool : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Malvern : Cabrini Hospital Malvern
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Murdoch :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Nedlands : Sir Charles Gairdner Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Nedlands : Hollywood Private Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Noble Park : South Eastern Private
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
North Adelaide :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Parkville : The Royal Melbourne Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Perth : Mount Medical Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Perth : Royal Perth Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Port Macquarie :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Prahran : Alfred Health
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Randwick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Ringwood : Ringwood/Knox Private
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Ringwood East : Maroondah Public
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Southport : Gold Coast Health Service District
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
St Leonards :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
St Leonards : Royal North Shore Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
St. Leonards : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Subiaco :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Sydney : Royal North Shore Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Townsville :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Tweed Heads : Tweed Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Wahroonga :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Waratah : Calvary Mater Newcastle
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Westmead : Westmead Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Woden :
A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)
Wodonga : Border Medical Oncology
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Wodonga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Wollongong : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Woodville South : Queen Elizabeth II Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Woodville South : The Queen Elisabeth Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Woolloongabba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Woolloongabba : Princess Alexandra Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Austria
Graz : Medizinische Universitat Graz
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Graz : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Innsbruck : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krems : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Linz : Krankenhaus der Barmherzigen Schwestern Linz
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Ried : Hospital BHS Ried
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
Salzburg : Salzburger Landesklinken
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Salzburg : Landeskrankenhaus Salzburg, Univ. Klinik für innere Medizin III, Universitätsklinikum der PMU
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
St Poelten : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Vienna : KH BHB Vienna
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
Vienna : Med. Univ. Vienna, General Hospital Vienna
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
Vienna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Vienna : 5th Med., Clinic Hietzing
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Vienna : University Vienna
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Wels : Klinikum Wels-Grieskirchen GmbH
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Wels : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wels : Klinikum Wels-Grieskirchen GmbH
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Wien : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien : Wilhelminenspital Wien
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Wien : Universitaetsklinik fur Innere Medizin
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Belgium
Aalst :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Aalst :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Aalst : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aalst : OL Vrouw Ziekenhuis Aalst Gastro-Enterologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Antwerp : Antwerp University Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
View More »
Antwerpen : Ziekenhuisnetwerk Antwerpen - AZ Middelheim
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Antwerpen :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Antwerpen : ZNA Middelheim
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Assebroek :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Bonheiden : Imelda VZW
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Bonheiden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Bonheiden :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Bonheiden : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bonheiden : Imelda Ziekenhuis
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Bonheiden : Imelda Ziekenhuis GI Clinical Research Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bornem :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Bornem : Sint-Josef Ziekenhuie (Campus Bornem)
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Brasschaat :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Brasschaat :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Brasschaat : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : AZ Sint-Lucas Brugge
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Brugge :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Brugge :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Brugge : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Brussels : Cliniques Universitaires St Luc
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Brussels : Erasme Hospital
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Brussels : Institut Jules Bordet - Centre de Tumeurs d'ULB
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Brussels : Cliniques Universitaires UCL St. Luc
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Bruxelles :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Charleroi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Charleroi : Grand Hospital de Charleroi
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Dendermonde :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Edegem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Edegem : Antwerp University Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Eupen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gent :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Gent :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Gent : UZ Gent
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Gent : AZ Middelares Gent
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Gent : Universiteits Ziekenhuis Gent
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Gent : AZ Maria Middelares
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Gent : University Hospital Gent
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Gilly : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Haine-saint-paul :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Haine-Saint-Paul : Hospital de Jolimont
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Haine-St.- Paul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Hasselt :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Hornu :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Ieper :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Kortrijk : AZ Groeninge - Campus Sint-Niklaas
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Kortrijk :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Leuven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Leuven :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Leuven : UZ Gasthuisberg
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Leuven : University Hospital, Gasthuisberg
Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27
Leuven : UZ Leuven, Campus Gasthuisberg
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Leuven : Leuven University Hospital - Campus Gasthuiseberg
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Liege :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Liege : Centre Hospitalier Universitaire de Liege
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Liège : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Lier :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Mechelen :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Mechelen :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Mechelen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Mechelen : AZ Sint Maarten Mechelen/Duffel
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Mechelen : VZW Emmaus St. Maarten Ziekenhuis Mechelen and St. Marten Ziekenhuis Duffel
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Mons :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Mons :
Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
Namur : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Oostende : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oudenaarde :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Reet : AZ Heilige Familie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Roeselare :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Ronse :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Seraing :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Sint-niklaas :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Sint-Niklaas : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Tongeren :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Turnhout :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Verviers :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Verviers : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wilrijk :
A Study of Avastin (Bevacizumab) With XELOX in Patients With Colorectal Cancer and Disease Progression on FOLFIRI and Avastin
Wilrijk :
An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)
Wilrijk : Sint-Augustinus Ziekenhuis
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Brazil
Ijui : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Rio De Janeiro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Salvador : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Sao Jose Do Rio Preto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Canada
Barrie : Royal Victoria Regional Health Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Edmonton : Cross Cancer Institute
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Greenfield Park : Hôpital Charles-LeMoyne
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Laval : Cité de la Santé de Laval
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
London : London Health Sciences Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Montreal : Maisonneuve-Rosemont Hospital Research Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Sudbury : Northeast Cancer Centre of Health Sciences North, Health Sciences North
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Thunder Bay : Thunder Bay Regional Health Sciences Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
Vancouver : British Columbia Cancer Agency - Vancouver Centre
Phase 2 study of PX-866 and cetuximab in patients with colorectal cancer or head and neck cancer.
View More »
Calgary : University of Calgary
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
Calgary : Tom Baker Cancer Centre
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Edmonton :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Greenfield Park : CSSS Champlain - Charles-Lemoyne Hospital
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Halifax : QEII Health Services Centre
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Laval : Hopital De La Cite-De-La-Sante
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Levis : CSSS Alphonse-Desjardins (CHAU Hotel-Dieu de Levis)
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
London : London Regional Cancer Program
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Montreal : Hopital Saint-Luc - Pavillon Principal
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Montreal : McGill University Health Centre
Multimodal Prehabilitation for Colorectal Surgery
Montreal : Montreal General Hospital
Prehabilitation to Overcome the Stress of Surgery: the Role of Nutrition in Enhancing Postoperative Functional Capacity
Montreal : CHUM-St. Luc Hospital
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Montreal : Jewish General Hospital
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Ottawa : Ottawa Health Research Institute - General Division
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Quebec : Hotel-Dieu de Quebec
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Sherbrooke : CHUS-Centre de recherche Etienne-Le Bel
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
St-Jérome : CSSS St-Jérome
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
Toronto : Novartis Investigative Site
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Vancouver : British Columbia Cancer Agency
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
China
Beijing :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Beijing : Peking University, People's Hospital
Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
Beijing : Peking University, School of Oncology
Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
Changzhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Chengdu :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
View More »
Fuzhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Guangzhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Hang Zhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Hangzhou :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Harbin :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Jiangsu :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Jinan :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Nanjing :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Shanghai :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Shanghai : Fudan University cancer hospital
Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer
Shenyang :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Wuhan :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Xian City :
An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer
Czech Republic
Brno : Masarykuv onkologicky ustav
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Brno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Hradec Kralove : Fakultni nemocnice Hradec Kralove
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Pardubice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Prague : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Praha 8 : Nemocnice Na Bulovce
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Denmark
Estonia
Tallinn :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Tartu :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Finland
France
Agen :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Aix En Provence :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Aix en Provence : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aix en Provence cedex 01 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Albi :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
View More »
Alencon :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Amiens :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Amiens : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amilly :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Amily :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Angers :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Arras :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Auch :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Avignon :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Bastia :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Bayonne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Beauvais :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Besançon Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Besancon :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Besancon : CHU de Becançon
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Besancon Cedex :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Bethune :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Beziers :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Bobigny :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Bordeaux : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Bordeaux :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Bordeaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bordeaux : CHU de Bordeau
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Boulogne Sur Mer :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Bourg En Bresse :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Bourg en Bresse : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Briis Sous Forges :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Brive La Gaillarde :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Brive la Gaillarde : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Caluire Et Cuire :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Cannes :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Carcassonne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Castelnau Lez :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Challes Les Eaux :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Champigny Sur Marne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Chateauroux :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Clermont-ferrand :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Colmar :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Colmar Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Compiegne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Creil :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Creteil :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Creteil : AERO
Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy
DAX :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Dijon :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Dijon : Centre Georges François Leclerc
Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Capecitabine Plus Mitomycin
Dijon cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Dreux :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Dunkerque :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Evreux :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Flers :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Frejus :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
GAP :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Gien :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Gonesse :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Hayange :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Hyeres :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
La Chaussee Saint Victor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
La Chaussee St Victor :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
La Roche Sur Yon :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
La Rochelle :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
La Seyne Sur Mer : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
La Tronche :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
La Tronche : Hospitalier Universitaire de Grenoble C.H.U.
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Lagny-sur-marne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Le Mans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Le Mans Cedex 9 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lille :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Longjumeau :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Longjumeau : Centre Hospitalier General de Longjumeau
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Longjumeau cedex 1 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lormont :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Lyon :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Mainvilliers :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Marseille :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Marseille : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Metz :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Metz Tessy :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Mont de Marsan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montauban :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Montbeliard :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Mont-de-marsan :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Montelimar :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Montfermeil :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Montivilliers :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Montpellier :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Montpellier : CRLC Val d'Aurelle
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Mougins :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Muret :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Nancy :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Nancy : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nantes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Narbonne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Neuilly-sur-seine :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Nevers :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Nice :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Nice : Hopital de l'Archet II, CHU de Nice
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Nimes :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Nogent Sur Marne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Orléans : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Orleans :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Osny :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Périgueux cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Paris :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Paris : Hospital European Georges Pompidou
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Paris Cedex 20 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Perigueux :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Perpignan :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Pessac :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Pierre Benite :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Poitiers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Pontoise Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pringy Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rambouillet :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Rang Du Fliers :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Reims : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rennes Cedex : Centre Eugène Marquis
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Rennes Cedex : Centre Eugene Marquis
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Rouen :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Rouen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Brieuc :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Saint Grégoire cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Jean :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Saint Quentin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Selestat :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Soissons Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soyaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
St Gregoire :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
St Lo :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
St Malo :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
St Martin Boulogne :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
St Quentin :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Strasbourg :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Strasbourg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Thonon-les-bains :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Toulouse :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Valence :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Vannes :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Venissieux :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Verdun :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Versailles :
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Vichy cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villefranche Sur Saone Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villejuif : Institut Gustave-Roussy
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Germany
Altstadt : Internistische Gemeinschaftspraxis
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Aschaffenburg : Klinikum Aschaffenburg
A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
Augsburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Augsburg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Balingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Bamberg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Berlin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Berlin : Charite Campus Virchow Klinikum
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bochum : Augusta Clinic
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Bonn : Johanniterkrankenhaus Bonn
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bonn : Universitaetsklinikum Bonn
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bonn : Braxiskooperation Bonn, Fachartze fur Innere Medizin
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Bremerhaven : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Essen : Kliniken Essen Mitte
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Essen : Gemeinschaftspraxis Hamatologie und internistische Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Frankfurt : Universitat Frankfurt Institute fur Diagnostic und Interventionelle Radiologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Frankfurt/Main : Krankenhaus Nordwest
Vaccination Against MSI Colorectal Cancer
Freiburg : iOMEDICO AG
Colorectal Cancer Registry
Fulda : MVZ Fulda
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Goslar : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Halle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Halle (Saale) : University Clinic - Internal Medicine I
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Halle/Saale : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hamburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Hamburg : Asklepios Klinik Altona, Abt. Radiologie, Neuroradiologie, Nuklearmedizin
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Hamburg : Universitastsklinikum Saarland
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Herdecke : Hospital Herdecke, private University
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Holzkirch : Praxisgemeinschaft Dr. med. Peter Sandor und Peter Kohl
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Ingolstadt : Onklogische Praxis Dr. Gerald Gehbauer
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Karlsruhe : Klinikum Karlsruhe, Stadtisches Klinikum Karlsruhe, Zentralinstitut fur Bildgebende Diagnostik
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Karlsruhe : Studienzentrale, St. Vicentius Kliniken gAG-Studienzentrale
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Kassel : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lübeck : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Magdeburg : Schwerpunktpraxis fur Hamatologie und Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Magdeburg : Klinikum Magdeburg GmbH, Klinik für Hämatologie/Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Magdeburg : Universitaetsklinikum Magdeburg
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Magdeburg : Clinic for Radiology and Nuclear Medicine
Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy
Magdeburg : Clinic for Radiology and Nuclear Medicine
Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
Mannheim : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marburg : Universitatsklinikum GieBen und Marburg
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Mönchengladbach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Muenchen : Klinikum Bogenhausen
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Muenchen : Klinikum der Universitaet Muenchen
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Munchen : Klinikum rechts der Isar der TU Munchen
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Munchen : Schwerpunktspraxis fur Hamatologie und Internistische Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Munchen : Hamato-Onkologische Schwerpunktspraxis
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Munich : Med. Clinic III, University Munich, Grosshadern
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Munich : Ludwig-Maximilians - University of Munich
Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
Neunkirchen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rotenburg (Wümme) : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soest : Clinic Kloster Paradiese
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Stralsund : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ulm : Med 1, University Clinic Ulm
Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)
Velbert : Praxis fur Hamatologie und Internnistische Onkologie
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Weiden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Weilheim : Schwerpunktspraxis und Tagesklinik Dr. Perker/Dr. Sandherr
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Greece
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Chania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Ioannina : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Hungary
Budapest : Orszagos Onkologiai Intezet
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Budapest :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Debrecen :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Gyor : Petz Aladar Megyei Oktato Korhaz
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
View More »
Gyor :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Gyula : Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Gyula :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Kaposvar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Kecskemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Kecskemet :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Kistarcsa :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Miskolc :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
National Institute Oncology : Medical Center of the University of Pecs
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Nyíregyháza :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Salgótarján :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Szeged :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Szekesfehervar :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Szekszard :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Szombathely :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Tatabanuya :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Veszprem :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
Zalaegerszeg :
AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer
India
Ahmedabad : Hemato-Oncology Clinic Ahmedabad PVT. Ltd Vedanta
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Kochin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Kolkata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Kolkata : Chittaranjan National Cancer Institute
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
View More »
Kolkata : B.P.Poddar Hospital and Medical Research Ltd.
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Mumbai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Mumbai : Shatabdi Superspeciality Hospital
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
New Delhi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Trivandrum : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Ireland
Cork : Bon Secours Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Dublin : St. Vincent's University Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Israel
Beer Sheva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Haifa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Haifa : Rambam Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Haifa : Elisha Hospital
Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy
Jerusalem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Jerusalem : Shaare-Zedek Medical Centre
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Netanya : Laniado Hospital
Performance Evaluation of the NaviAid™ G-Eye System
Petah Tikva : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Petah Tiqva : Rabin Medical Center, Beilinson Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Ramat Gan : Sheba Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Tel Aviv : TA Sourasky Medical Center
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Tel Hashomer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tel-Aviv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Italy
Albano Laziale :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Ancona : Az Osp. Univ. Ospedali Riuniti 'Umberto I G.M Lancisi G.Salesi'
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Ancona :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Benevento :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Biella :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
View More »
Bologna :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Bologna : A.O.U. die Bologna
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Brescia :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Brescia : Fondazione Poliambulanza
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Brindisi :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Candiolo : Fondazione del Piemonte per I'Oncologia IRCC
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Castellana Grotte (ba) :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Catania :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Catania :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Cefalù PA : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cefalu :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Chieti :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Como :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Cosenza :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Cremona :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Cuneo :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Este :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Este (pd) :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Fano :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Ferrara :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Foggia :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Genova : IRCCS Azienda Ospedaliera Universitaria San Martino - Istituto Nazionale per la Ricerca sul Cancro
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Genova : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Genova :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Genova : Universita Delgi Studi de Genova (UNIGE)- Azienda Ospedaliera. Universitaria "San Martino" (Ospedale San Martino)
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Grosseto :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Imola (bo) :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
La Spezia :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Lamezia Terme (cz) :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
L'aquila :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Lecce :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Lecco :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Lido Di Camaiore :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Livorno :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Macerata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Macerata :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Messina :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Milan : A.O. Ospedale Niguarda Ca' Granda
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Milano :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Milano :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Mirano (ve) :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Modena :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Modena :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Montecchio Maggiore :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Monza :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Napoli :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Napoli :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Napoli : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Napoli : Seconda Università degli Studi di Napoli
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Novara :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Orbassano :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Orbassano : AOU San Luidi di Orbassano
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Padova : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Padova :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Padova : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Parma :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Pavia :
A Study of Avastin (Bevacizumab) and FOLFOX in Patients With Colorectal Cancer
Pavia :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Perugia :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Pisa : Azienda Ospedaliero
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Pontedera :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Pordenone :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Reggio Calabria :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Reggio Emilia : Arcispedale Santa Maria Nuova
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Reggio Emilia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Rionero in Vulture :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Roma :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Roma : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Rovigo :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Rozzano (MI) : Istituto Clinico Humanitas
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
San Giovanni Rotondo :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Saronno :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Sassari :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Savona :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Siena :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Sondrio : Ospedale di Sondrio
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Sora :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Taormina :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Teramo :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Torino :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Torino : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Treviso :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Varese :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Vimercate :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Viterbo :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)
Japan
Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Chiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Chiba : Chiba Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Chuo-ku : National Cancer Center Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Ehime : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Fukuoka : National Hospital Organization Kyushu Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Gifu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Kashiwa : National Cancer Center Hospital East
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Kita-adachi-gun : Saitama Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Kobe : Kobe City Medical Center General Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Kochi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Koto-ku : The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Kumamoto : Kumamoto University Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Matsuyama : National Hospital Organization Shikoku Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Nagoya : Aichi Cancer Center Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Oita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Osaka : Osaka Medical Center for Cancer and Cardiovascular Diseases
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Sapporo : KKR Sapporo Medical Center TONAN-Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Sapporo : Hokkaido University Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Shimotsuke : Jichi Medical University Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Shinjuku-ku : Keio University Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Shizuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Sunto-gun : Shizuoka Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Takatsuki : Osaka Medical College Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Tochigi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tokushima : Tokushima University Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Tsukuba : Tsukuba University Hospital
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Yokohama : Kanagawa Cancer Center
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Korea, Republic of
Anyang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Goyang-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Incheon : Inha University Hospital
Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Lebanon
Beirut :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Dora :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
El Chouf :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
El- Metn :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Jbeil :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
View More »
Saida :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Tripoli :
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Netherlands
Amstelveen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amsterdam : Novartis Investigative Site
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Breda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Den Haag : HagaZiekenhuis
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Deventer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Dordrecht : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Eindhoven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Enschede : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Groningen : Universitair Medisch Centrum Groningen
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Groningen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Leiden : LUMC
Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study
Leiderdorp : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Purmerend : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roosendaal : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rotterdam : Erasmus MC
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Sittard - Geleen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Utrecht : Universitair Medisch Centrum Utrecht
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
Utrecht : UMC Utrecht
Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study
Vlissingen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zutphen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
New Zealand
Auckland : University of Auckland
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Christchurch : Christchurch Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Dunedin : Dunedin Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Newtown : Wellington Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Palmerston : Palmerston North Hospital
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Norway
Oslo :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Poland
Bialystok : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gdansk : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Koszalin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lubin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Olsztyn : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Poznan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Walbrzych : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Warsaw : Wojskowy Instytut Medyczny (WIM)
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Warszawa : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wroclaw : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Portugal
Coimbra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Evora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Lisboa :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Porto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Porto :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Puerto Rico
Romania
Alba Iulia : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Baia-Mare : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasov : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Bucharest :
An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)
View More »
Bucharest :
An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)
Bucharest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cluj-Napoca : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Cluj-Napoca : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Iasi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Oradea : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Oradea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ramnicu Valcea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Targu Mures : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Serbia
Belgrade :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)
Kragujevac :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)
Kragujevac :
An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)
NIS :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)
Sremska Kamenica :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)
Slovakia
Banska Bystrica :
An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer
Banska Bystrica :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Bardejov : St.James Hospital and Clinic
Prevention of Irinotecan Induced Diarrhea by Probiotics
Bratislava :
An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer
Bratislava :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
View More »
Bratislava : National Cancer Institute, Slovakia
Prevention of Irinotecan Induced Diarrhea by Probiotics
Bratislava : Oncologic Institute of St.Elisabeth OUSA
Prevention of Irinotecan Induced Diarrhea by Probiotics
Komarno : Zdravspol s r.o. - oncologic ambulance
Prevention of Irinotecan Induced Diarrhea by Probiotics
Kosice :
An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer
Kosice :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Košice : National cancer Institute
Prevention of Irinotecan Induced Diarrhea by Probiotics
Martin :
An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer
Martin :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Nitra :
An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer
Nitra :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Poprad :
An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer
Poprad :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Poprad : POKO Poprad Ltd.
Prevention of Irinotecan Induced Diarrhea by Probiotics
Presov :
An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer
Presov :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Ruzomberok :
An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer
Ruzomberok :
An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer
Trencin : Faculty Hospital Trencin
Prevention of Irinotecan Induced Diarrhea by Probiotics
Slovenia
Spain
Barcelona : Hospital Vall D'Hebron
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Barcelona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Barcelona : Hospital Universitari Vall d'Hebron
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Barcelona : Institut Català d'Oncologia
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
La Coruna : Centro Oncologico de Galicia
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
View More »
Madrid : Centro Integral Oncologico Clara Campal
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Madrid : Spanish Cooperative Group for Gastrointestinal Tumour Therapy
Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases
Madrid : Spanish Cooperative Group for Gastrointestinal Tumour Therapy
Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer
Madrid : Hospital Universitario Ramon y Cajal
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Oviedo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Pamplona : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Pamplona : Clinica Universitaria de Navarra
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Pamplona : Hospital de Navarra, Servicio de Ongoligia, Planta Baja
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Sabadell : Corporacio Sanitaria Parc Tauli
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Sabadell : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Santander : Hospital Universitario Marques de Valdecilla
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Santander : Hospital Universitario Marqués de Valdecilla
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Sevilla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Sevilla : Hospital Universitario Virgen del Rocío
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Terrassa : Hospital Mutua de Terrassa
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Valencia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Valencia : Hospital Clinico Universitario De Valencia
Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer
Zaragoza : Hospital Universitario Miguel Servet
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Sweden
Switzerland
Aarau :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Basel :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Luzern :
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Zurich : Universitatsspital Zurich
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
Taiwan
Kaohsiung : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Kuei Shan Hsiang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Taichung : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Taichung :
An Observational Study of Avastin (Bevacizumab) With First-Line Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer
Tainan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
View More »
Taipei : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Second Line Metastatic Colorectal Cancer
Taipei :
An Observational Study of Avastin (Bevacizumab) With First-Line Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer
United Kingdom
Aberdeen : Aberdeen Royal Infirmary
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Birmingham :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Bristol :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Cambridge : Addenbrooke's Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Carlisle :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
View More »
Chelsmford :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Dudley :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Edinburgh : Western General Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Glasgow : Beatson West of Scotland Cancer Center
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Ipswich :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Kidderminster :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
London : University College Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Macclesfield :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Maidstone : Maidstone Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Manchester : Christie Hospital
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Manchester : Christie Hospital NHS Foundation Trust
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Northwood, Essex :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Nottingham :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Peterborough : Peterborough and Stamford Hospitals NHS Foundation Trust
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
Peterborough :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Romford :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Stafford :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Sutton :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Swindon :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Torquay :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Truro :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Winchester :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
Wolverhampton :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
